Steven King has been President and Chief Executive Officer of Peregrine since March 2003. Mr. King started with Peregrine in 1997 as the Director of Research and Development. He first was promoted to Senior Director of Research and Development and then to Vice President of Technology and Product Development. In 2000, Mr. King was also given the responsibility of bringing the company’s biologics manufacturing facility into full cGMP compliance and then launching its wholly owned contract manufacturing subsidiary, Avid Bioservices. Since 2001, Mr. King has served as the President and CEO of Avid Bioservices, and was promoted to Peregrine’s Chief Operating Officer at that time. Prior to joining Peregrine, Mr. King was employed at a corporation that was developing Vascular Targeting Agents (VTA), which was acquired by Peregrine in 1997. Mr. King previously worked with Dr. Philip Thorpe, inventor of the VTA technology, at the University of Texas Southwestern Medical Center at Dallas and is a co-inventor on over 25 U.S. and foreign patents and patent applications in the VTA area. Mr. King holds BS and MS degrees in Biology from Texas Tech University.

Paul Lytle has served as Chief Financial Officer since August 2002. Mr. Lytle oversees Finance & Accounting, SEC Reporting, Investor Relations, Human Resources and Information Technology. Mr. Lytle started with Peregrine in March 1997 as Corporate Controller and has held positions of increasing responsibility at the company. Mr. Lytle was promoted to Vice President of Finance and Accounting and was elected as the company's Corporate Secretary in 2000. Mr. Lytle has been responsible for the development and implementation of numerous technology initiatives, increasing the company's efficiency in many areas, including finance. Mr. Lytle implemented a new interfaced accounting system and oversaw the installation of company networks and management information systems. During his tenure, Peregrine has raised over $100 million in equity financing from the public markets. Prior to joining Peregrine, Mr. Lytle worked for Deloitte & Touche LLP. Mr. Lytle holds a BS in Business Administration from the California State University at Long Beach and is a certified public accountant in the State of California and a member of the American Institute of Certified Public Accountants.

Dr. Garnick has over 30 years of experience in Drug and biologic pharmaceutical development. He was formerly the Senior Vice President of Regulatory, Quality and Compliance at Genentech, Inc. Dr. Garnick spent 24 years at Genentech helping to found the biotechnology industry. While at genentech Dr. Garnick was responsible for the approval of over 17 drugs, biologics and medical devices. He has extensive experience in analytical methodology, process validation, the regulatory review process both in the US and Europe and in Risk assessments. He has authored numerous scientific papers and has given numerous keynote presentations to the pharmaceutical Industry.

Dr. Garovoy has over 15 years of experience in designing and conducting of clinical trials. Prior to Peregrine, he held positions as chief medical officer at Arriva Pharmaceuticals, and as senior vice president of clinical development at Hyperion Therapeutics. For most of the previous decade, Dr. Garovoy held senior clinical positions at XOMA, including vice president of clinical science. In addition to overseeing clinical development programs at XOMA, he was responsible for managing clinical collaborations with external partners. Dr. Garovoy played a major role in the successful clinical development, regulatory approval and commercial launch of Raptiva®, a monoclonal antibody drug for the treatment of psoriasis jointly developed by XOMA and Genentech. He has authored over 200 medical publications and holds two patents. He held teaching positions as a faculty member at Harvard Medical School and more recently as a Professor of Surgery and Medicine at the University of California, San Francisco. Dr. Garovoy received a BA degree from New York University, an M.D. degree with honors from the State University of New York Downstate Medical Center, and completed a post-graduate fellowship in Immunology and Transplantation at Harvard Medical School.

Joseph Shan has been serving as Peregrine's head of Clinical and Regulatory Affairs since January 2003. He is responsible for helping to design and execute Peregrine's clinical trials and overseeing regulatory submissions. Since joining Peregrine in 2000, Mr. Shan has been instrumental in advancing the clinical development of the company's bavituximab and Cotara® antibody products. Prior to joining Peregrine, Mr. Shan held positions of increasing responsibility in clinical and regulatory affairs at Edwards Lifesciences (formerly Baxter Healthcare Corporation) and Sulzer Medica. Mr. Shan received his B.S. degree in Physiological Sciences from the University of California, Los Angeles and his M.P.H. degree from the George Washington University in Washington, DC. He is a member of the American Society of Clinical Oncology, the Association of Clinical Research Professionals and the Regulatory Affairs Professionals Society.

Truc Le joined Avid Bioservices, Inc. as Chief Operating Officer in July 2009. Mr. Le has over 30 years of extensive experience in the field of Worldwide Operations, Quality Systems Management, and Business Effectiveness. Prior to joining Avid Bioservices, Mr. Le was Senior V.P. of Operations and Corporate Quality for Nektar Therapeutics, a biopharmaceutical company. His responsibilities included manufacturing, supply chain, materials, purchasing, facility, ERP implementation, quality management, and compliance. Prior to joining Nektar, Mr. Le was employed by a division of Johnson & Johnson for 20 years as the Worldwide Vice-President of Regulatory Compliance and Quality Systems and a member of Executive Management. Mr. Le is also a co-founder of a consulting firm, MLH Group, specializing in Global Operations, Regulatory Affairs, Quality Management, and Business Excellence for Pharmaceutical, Biotechnology, Medical Device, In Vitro Diagnostics (IVD) industry as well as drug/device combination products. Mr. Le has been assisting numerous companies ranging from start-up to Fortune 100 corporations in developing their Operations and Regulatory Affairs that meet U.S. FDA and International Standards, including achievements of ISO registration and CE mark approval for European Union. He has also assisted companies in Business Excellence utilizing Six Sigma techniques improving operational efficiency and effectiveness. Mr. Le has a BS in mechanical engineering, MBA in Management, and completed numerous executive leadership training programs, including World Class Manufacturing at Duke University, Executive Management at Harvard University, and a QSR trainer at AAMI/FDA.

Shelley Fussey joined Peregrine as Vice President, Intellectual Property in February 2005. Dr. Fussey will play a key role in Peregrine's US and international patenting, patent analysis and patent defense. An expert in European opposition procedures, portfolio analysis and counseling in the biotechnology arena, Dr. Fussey's expertise includes patent strategy for technologies developed both in-house and in-licensed from universities. She has broad experience in intellectual property consulting for areas as complex as cancer treatment, immunology, diabetes, and antiviral technology, as well as other areas central to pharmaceutical and biotechnology drug development. Prior to joining Peregrine, Dr. Fussey worked for the law firms of Williams, Morgan & Amerson and Arnold, White and Durkee. She holds a Ph.D. in Biochemistry, and a B.Sc. in Biochemistry with First Class Honours (Summa Cum Laude) from the University of Newcastle upon Tyne, UK.

Richard Richieri has over ten years of experience in the biologics industry manufacturing proteins and antibodies. At Peregrine, as director of manufacturing,  he was responsible for process development and manufacture of clinical trial materials. At Avid Bioservices, Mr. Richieri is responsible for all manufacturing including process development and facilities. Prior to joining Peregrine, he worked at Xoma Corporation where he was responsible for large-scale manufacturing and mammalian cell culture process development. Mr. Richieri received his Bachelor’s degree from University of California, Los Angeles (UCLA) in Chemical Engineering and his M.S. from University of California, San Diego (UCSD) studying the dependency of antibody production on cell cycle kinetics. Mr. Richieri is licensed as an Exemptee Pharmacist by the Board of Pharmacy State of California.

John L. Quick has been associated with Peregrine and Avid since mid-2004 as a consultant on quality and regulatory compliance. He is founder of Quick & Associates a consulting firm devoted to quality, regulatory compliance and new product development consulting.  Mr. Quick retired from Baxter International after a 37 year career with the company with responsibility for new product development and quality management . In 1998, Mr. Quick was appointed corporate vice president quality/regulatory compliance responsible for all worldwide quality and regulatory compliance at Baxter, reporting to the Chairman and CEO, a position he held until his retirement.  Mr. Quick is immediate past Chairman of the Board of the Lincoln Foundation for Performance Excellence and is Vice Chairman of the Board of Methodist Hospital of Chicago and its parent corporation.   Mr. Quick has an undergraduate degree in Chemistry from Indiana University and an MBA from the Northwestern J.L. Kellogg Graduate School of Management.  He holds three issued patents and has made numerous industry presentations on the subject of quality and regulatory compliance.

Dr. Boyd has more than 20 years of international pharmaceutical and biotechnology business development experience with large pharmaceutical companies including GlaxoSmithKline, Novartis and Roche. Dr. Boyd was previously director, Asia, worldwide business development, R&D for GlaxoSmithKline; head of business development and licensing in Japan for Novartis; and head, licensing and patent group for Roche in Japan. In these positions, she identified new opportunities, negotiated global agreements and maintained productive relationships with other companies. Dr. Boyd holds a Ph.D. in Developmental Genetics from the University of Cambridge, UK and a B.Sc. in Biochemistry from the University of Sussex, UK.